Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | CASP3 | P42574 | 2/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | STAT3 | P40763 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | APP | P05067 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982896 | 0.91 | RAB9A (0.68) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL10172979 | 0.91 | RAB9A (0.86) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL9788664 | 0.87 | RAB9A (1.00) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL2257167 | 0.86 | RAB9A (0.77) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL13191467 | 0.86 | RAB9A (0.77) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL4147937 | 0.86 | RAB9A (0.77) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL11407545 | 0.85 | RAB9A (0.76) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| Bromide SCHEMBL1691440 | 0.84 | RAB9A (0.75) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| Bromide SCHEMBL1691646 | 0.84 | RAB9A (0.75) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 | |
| SCHEMBL1984138 | 0.81 | RAB9A (0.84) | RAB9ANPC1ALDH1A1SMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | claimed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | claimed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | claimed |
| EP-3063150-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3063150-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9765070-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9765070-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9765070-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-19 | — | — | US | disclosed |
| US-20160272637-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160272637-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272637-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | RAB9A 1951/4885NPC1 2232/4885ALDH1A1 2345/4885 |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | NOS1, PTGIS, NOS2 | RAB9A 2234/4885NPC1 2959/4885ALDH1A1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.